Ultragenyx Pharmaceutical Inc. (RARE) - What Are Investment Firms Saying About This Stock?

Key Points

• Analyst sentiment is mixed: 22 firms give Ultragenyx an average “Hold” rating (11 holds, 9 buys, 1 strong buy, and 1 sell), with an average 12-month price target of $29.79.
• Recent price targets vary widely: Jefferies cut its target from $77 to $28 while retaining a “Buy”; Wells Fargo raised its target to $19 with an “Equal Weight” rating, and Barclays lowered its target to $32 while remaining “Overweight.”
• Quarterly results missed estimates: Ultragenyx reported an adjusted loss of $1.16 per share and $173 million in revenue, below consensus estimates, though revenue grew 8.2% year over year. Shares traded at $16.08, well below their 12-month high of $39.89.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has received an average recommendation of "Hold" from the twenty-two research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation, nine have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $29.79.

A number of research analysts recently issued reports on the company. Jefferies Financial Group cut their price objective on Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a "buy" rating for the company in a research note on Thursday, September 3rd. Wells Fargo & Company raised their target price on shares of Ultragenyx Pharmaceutical from $18.00 to $19.00 and gave the stock an "equal weight" rating in a research note on Wednesday, November 4th. UBS Group initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Thursday, October 15th. They set a "neutral" rating and a $16.00 target price on the stock. Barclays lowered their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $32.00 and set an "overweight" rating on the stock in a report on Thursday, November 5th. Finally, Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE traded down $0.19 during midday trading on Friday, hitting $16.08. The company had a trading volume of 1,679,424 shares, compared to its average volume of 3,590,241. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -3.10 and a beta of 0.37. The company has a fifty day moving average of $15.29 and a two-hundred day moving average of $22.52. Ultragenyx Pharmaceutical has a 12-month low of $12.73 and a 12-month high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The business had revenue of $173.00 million during the quarter, compared to analyst estimates of $182.49 million. During the same period in the previous year, the company earned ($1.81) earnings per share. The business's revenue for the quarter was up 8.2% compared to the same quarter last year. Research analysts expect that Ultragenyx Pharmaceutical will post -3.21 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Howard Horn sold 7,066 shares of the business's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $15.27, for a total value of $107,897.82. Following the transaction, the chief financial officer directly owned 89,229 shares in the company, valued at $1,362,526.83. The trade was a 7.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,510 shares of company stock worth $127,561 over the last quarter. 5.20% of the stock is owned by company insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in Ultragenyx Pharmaceutical during the 2nd quarter valued at approximately $355,746,000. GW&K Investment Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 55.8% in the third quarter. GW&K Investment Management LLC now owns 2,307,844 shares of the biopharmaceutical company's stock worth $34,687,000 after buying an additional 826,666 shares in the last quarter. Jefferies Financial Group Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 44.1% during the third quarter. Jefferies Financial Group Inc. now owns 1,339,814 shares of the biopharmaceutical company's stock worth $20,137,000 after acquiring an additional 410,188 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth $38,347,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Ultragenyx Pharmaceutical by 20.4% during the third quarter. Russell Investments Group Ltd. now owns 944,240 shares of the biopharmaceutical company's stock worth $14,256,000 after acquiring an additional 160,141 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.